Assessment of plasma brain-derived neurotrophic factor (BDNF), activity-dependent neurotrophin protein (ADNP) and vasoactive intestinal peptide (VIP) concentrations in treatmentnaïve humans with multiple sclerosis

Neuroendocrinology Letters

Volumn 36, Issue 2, 2015, Pages 148-152

  Kochanowski, Jan ^a   Uchman, Dorota ^a   Litwiniuk, Anna ^b   Kalisz, Malgorzata ^b   Wolinska Witort, Ewa ^b   Martynska, Lidia ^b   Baranowska, Boguslawa ^a   Bik, Wojciech ^b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

ADNP; BDNF; Multiple sclerosis; VIP

Indexed keywords

ACTIVITY DEPENDENT NEUROTROPHIN PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; NEUROTROPHIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; ADNP PROTEIN, HUMAN; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; HOMEODOMAIN PROTEIN; NERVE PROTEIN;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; BLOOD; MIDDLE AGED; YOUNG ADULT;

ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVE TISSUE PROTEINS; VASOACTIVE INTESTINAL PEPTIDE; YOUNG ADULT;

EID: 84937439125     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Abad C, Tan YV, Lopez R, Nobuta H., Dong H, Phan P, et al. (2010). Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 107(45): 19555-19560.
2. Abad C, Waschek JA (2011). Immunomodulatory roles of VIP and PACAP in models of multiple sclerosis. Curr Pharm Des 17(10): 1025-1035.
3. Azoulay D, Vachapova V, Shihman B., Miler A, Karni A (2005). Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol 167(1-2):215-218.
4. Baranowska-Bik A, Kochanowski J, Uchman D., Wolinska-Witort E, Kalisz M, Martynska L., et al. (2013). Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) in humans with multiple sclerosis. J Neuroimmunol 263(1-2): 159-161.
5. Barde YA, Edgar D, Thoenen H (1982). Purification of a new neurotrophic factor from mammalian brain. EMBO J 1(5): 549-553.
6. Braitch M, Kawabe K, Nyirenda M., Gilles LJ, Robins RA, Gran B, et al. (2010). Expression of activity-dependent neuroprotective protein in the immune system: possible functions and relevance to multiple sclerosis. Neuroimmunomodulation. 17(2): 120-125.
7. Calabrese F, Rossetti AC, Racagni G, Gass P., Riva MA, Molteni R (2014). Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. Front Cell Neurosci 8:430.
8. Comini-Frota ER, Rodrigues DH, Miranda E.C., Brum DG, Kaimen-Maciel DR, Donadi EA, et al. (2012). Serum levels of brain-derived neurotrophic factor correlate with the number of T2 MRI lesions in multiple sclerosis. Braz J Med Biol Res 45(1): 68-71.
9. Damasceno A, Damasceno BP, Cendes F, Moraes A.S., Farias A., Santos LM (2015). Serum BDNF levels are not reliable correlates of neurodegeneration in MS patients. Mult Scler Relat Disord 4(1): 65-66.
10. Frota ER, Rodrigues DH, Donadi E.A., Brum DG, Maciel DR, Teixeira AL (2009). Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse. Neurosci Lett 460(2): 130-132.
11. Gozes I (2012). Neuropeptide GPCRs in neuroendocrinology: the case of activity-dependent neuroprotective protein (ADNP). Front Endocrinol (Lausanne) 3:134.
12. Gozes I, Bassan M, Zamostiano R., Pinhasov A, Davidson A, Giladi E., et al. (1999). A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein. Ann N Y Acad Sci 897:125-135.
13. Hohlfeld R (2008). Neurotrophic cross-talk between the nervous and immune systems: relevance for repair strategies in multiple sclerosis? J Neurol Sci 265(1-2): 93-96.
14. Kamm CP, Uitdehaag BM, Polman CH (2014). Multiple Sclerosis: Current Knowledge and Future Outlook. Eur Neurol 72(3-4): 132-141.
15. Kerschensteiner M, Gallmeier E, Behrens L., Leal VV, Misgeld T, Klinkert WE, et al. (1999). Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 189(5): 865-870.
16. Kerschensteiner M, Stadelmann C, Dechant G., Wekerle H, Hohlfeld R (2003). Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 53(3): 292-304.
17. Lalive PH, Kantengwa S, Benkhoucha M., Juillard C, Chofflon M (2008). Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients. J Neuroimmunol 197(2): 147-151.
18. Linker RA, Lee DH, Demir S, Wiese S., Kruse N, Siglienti I, et al. (2010). Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain. 133(Pt 8): 2248-2263.
19. Luhder F, Gold R, Flugel A., Linker RA (2013). Brain-derived neurotrophic factor in neuroimmunology: lessons learned from multiple sclerosis patients and experimental autoimmune encephalomyelitis models. Arch Immunol Ther Exp (Warsz) 61 (2): 95-105.
20. McFarland HF, Martin R (2007). Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol. 8(9): 913-919.
21. Noble EE, Billington CJ, Kotz C.M., Wang C (2011). The lighter side of BDNF. Am J Physiol Regul Integr Comp Physiol. 300(5): R1053-1069.
22. Numakawa T, Adachi N, Richards M., Chiba S, Kunugi H (2013). Brain-derived neurotrophic factor and glucocorticoids: reciprocal influence on the central nervous system. Neuroscience 239: 157-172.
23. Rostami A, Ciric B (2013). Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination. J Neurol Sci 333(1-2): 76-87.
24. Stadelmann C, Kerschensteiner M, Misgeld T., Bruck W, Hohlfeld R, Lassmann H (2002). BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 125(Pt 1): 75-85.
25. Sun W, Hong J, Zang Y.C., Liu X., Zhang JZ (2006). Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. Int Immunol 18(12): 1691-1700.
26. Tan YV, Waschek JA (2011). Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis. ASN Neuro 3(4). doi:10.1042/AN20110024.
27. Tongiorgi E, Sartori A, Baj G., Bratina A, Di Cola F, Zorzon M, et al. (2012). Altered serum content of brain-derived neurotrophic factor isoforms in multiple sclerosis. J Neurol Sci 320(1-2): 161-165.
28. Waschek JA (2013). VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair. Br J Pharmacol 169(3): 512-523.
29. Yoshimura S, Ochi H, Isobe N., Matsushita T, Motomura K, Matsuoka T., et al. (2010). Altered production of brain-derived neurotrophic factor by peripheral blood immune cells in multiple sclerosis. Mult Scler 16(10): 1178-1188.
30. Zusev M, Gozes I (2004). Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regul Pept 123(1-3): 33-41.